2022
DOI: 10.1177/10600280221132019
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections

Abstract: Background: Carbapenem-resistant Enterobacterales (CRE) are difficult to treat and can cause significant morbidity and mortality, however most data reflect carbapenemase-producing infections. Objective: Our objective was to evaluate clinical outcomes of non-carbapenemase-producing CRE (nCP-CRE) compared with carbapenem-susceptible Enterobacterales (CSE) infections. Methods: This was a retrospective, multicenter, observational study (January 1, 2018 to December 31, 2020). The primary outcome was clinical succes… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 39 publications
0
1
0
Order By: Relevance
“…Numerous clinical studies have investigated carbapenem efficacy in infections caused by carbapenemase-producing and non-producing Enterobacterales [21][22][23][24][25]. However, these studies did not highlight strains with meropenem MICs below the resistance breakpoint (2-4 mg/L) that might also harbor carbapenemase genes.…”
Section: Discussionmentioning
confidence: 99%
“…Numerous clinical studies have investigated carbapenem efficacy in infections caused by carbapenemase-producing and non-producing Enterobacterales [21][22][23][24][25]. However, these studies did not highlight strains with meropenem MICs below the resistance breakpoint (2-4 mg/L) that might also harbor carbapenemase genes.…”
Section: Discussionmentioning
confidence: 99%